Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Shunichi Jinnai"'
Autor:
Shunichi Jinnai, Naoya Yamazaki, Yuichiro Hirano, Yohei Sugawara, Yuichiro Ohe, Ryuji Hamamoto
Publikováno v:
Biomolecules, Vol 10, Iss 8, p 1123 (2020)
Recent studies have demonstrated the usefulness of convolutional neural networks (CNNs) to classify images of melanoma, with accuracies comparable to those achieved by dermatologists. However, the performance of a CNN trained with only clinical image
Externí odkaz:
https://doaj.org/article/d376c4bf38824dcd9acf956f77a4fbd8
Publikováno v:
The Journal of dermatologyREFERENCES.
The efficacy and safety of nivolumab and ipilimumab (N + I) combination therapy for Japanese patients with advanced unresectable melanoma was re-evaluated in clinical practice. One hundred Japanese patients with advanced melanoma were included. The o
Publikováno v:
Dermatology Online Journal. 28
Autor:
Akihiro Ishiguro, Dai Ogata, Kae Okuma, Tairo Kashihara, Naoya Murakami, Kojiro Hiki, Kohei Yamakawa, Shunichi Jinnai, Akira Takahashi, Kenjiro Namikawa, Hiroshi Igaki, Naoya Yamazaki
Publikováno v:
The Journal of dermatologyREFERENCES.
Malignant melanoma (MM) is usually resistant to radiotherapy. Brachytherapy may be an option in patients with bleeding or pain, and those in whom surgery is difficult. Brachytherapy has few side effects and can be used in combination with external be
Autor:
Kohei Yamakawa, Dai Ogata, Kojiro Hiki, Shunichi Jinnai, Kenjiro Namikawa, Akira Takahashi, Naoya Yamazaki
Publikováno v:
International Journal of Dermatology. 62
Autor:
Haruki Mizuta, Eiji Nakano, Naoya Yamazaki, Yuta Kage, Shunichi Jinnai, Arata Tsutsumida, Yusuke Muto, Akira Takahashi, Kenjiro Namikawa
Publikováno v:
The Journal of Dermatology. 47:622-628
Treatment for patients with unresectable melanoma has been dramatically changed by the use of immunocheckpoint inhibitors (ICI). In this study, we reviewed patients with unresectable stage III/IV melanoma, who were treated with nivolumab between July
Autor:
Dai Ogata, Keita Tsutsui, Kenjiro Namikawa, Konosuke Moritani, Kenta Nakama, Shunichi Jinnai, Akira Takahashi, Shunsuke Tsukamoto, Yukihide Kanemitsu, Naoya Yamazaki
Publikováno v:
Journal of cancer research and clinical oncology.
Primary anorectal melanoma (ARM) accounts for approximately 1.2% of all melanomas and 16.5% of all mucosal melanomas. ARM is associated with the shortest interval to disease progression and the highest rate of metastasis; however, optimal therapeutic
Publikováno v:
International journal of dermatologyReferences. 61(7)
In most cutaneous melanomas of the distal extremity, sentinel lymph nodes (SLNs) are identified in the axillary or inguinal basin; however, they may be occasionally found in the epitrochlear or popliteal basins. The incidence and patterns of lymphati
Autor:
Akihiro, Ishiguro, Dai, Ogata, Ken, Ohashi, Kojiro, Hiki, Kohei, Yamakawa, Shunichi, Jinnai, Keita, Tsutsui, Akira, Takahashi, Kenjiro, Namikawa, Naoya, Yamazaki
Publikováno v:
Medicine. 101:e30398
Advanced malignant melanoma (MM) is treated with immune checkpoint inhibitor (ICI) therapy, which often results in several immune-related adverse events. Fulminant type 1 diabetes mellitus (T1DM) is a rare, rapidly progressive, life-threatening disea
Autor:
Masaki Otsuka, Kenjiro Namikawa, Shunichi Jinnai, Takeru Funakoshi, Naoya Yamazaki, Dai Ogata, Keiji Tanese, Keita Tsutsui, Akira Takahashi, Yoshio Kiyohara, Kenta Nakama, Yoshio Nakamura, S. Yoshikawa
Publikováno v:
International journal of clinical oncology. 26(12)
Completion lymph node dissection (CLND) has long been the standard treatment for stage III melanomas identified as metastasis on the sentinel node (SN-positive). Two major changes occurred in 2017 and 2018, the change in the CLND criteria for SN-posi